Effect of Pimavanserin on the Respiratory Arousal Threshold from Sleep: A Randomized Trial.

ABSTRACT: Rationale: A low respiratory arousal threshold is a key endotype responsible for obstructive sleep apnea (OSA) pathogenesis. Pimavanserin is an antiserotoninergic capable of suppressing CO₂-mediated arousals without affecting the respiratory motor response in animal models, and thus it holds potential for increasing the arousal threshold in OSA and subsequently reducing OSA severity. Objectives: We measured the effect of pimavanserin on arousal threshold (primary outcome), OSA severity, arousal index, and other OSA endotypes (secondary outcomes). Methods: A total of 18 OSA participants were studied in a randomized, double-blind, crossover study. Patients received a single dose of placebo or pimavanserin 34 mg 4 hours before in-lab polysomnography. Airflow wa

SUBMITTER: Messineo L 

PROVIDER: S-EPMC9743476 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature